FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

Share this content:
FDA OKs Lynparza to Treat Breast Cancer With <i>BRCA</i> Mutation
FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

FRIDAY, Jan. 12, 2018 (HealthDay News) -- Lynparza (olaparib) has been approved by the U.S. Food and Drug Administration to treat metastatic breast cancer caused by a BRCA gene mutation.

Lynparza, a poly ADP-ribose polymerase (PARP) inhibitor, was evaluated to treat breast cancer in clinical studies involving 302 participants. Patients who took the drug had an average seven months of progression-free survival, compared to 4.2 months among patients who were given only chemotherapy.

Lynparza's most common side effects included anemia, neutropenia, leukopenia, nausea, fatigue, vomiting, cold-like symptoms, and respiratory tract infections. More serious adverse reactions could include development of myelodysplastic syndrome/acute myeloid leukemia and pneumonitis, the FDA said. The drug shouldn't be taken by women who are pregnant, hoping to become pregnant, or breast-feeding, the agency warned.

"This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, said in a statement. "This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of cancer, often across cancer types."

Lynparza is produced by the British drug maker AstraZeneca, whose U.S. headquarters are in Wilmington, Del.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Medicare Requiring Hospitals to Post Prices Online

Medicare Requiring Hospitals to Post Prices Online

Medicare would base part of a hospital's payments on how easy it is for patients to access medical records

Restless Brain Syndrome Tied to Changes in the Brain

Restless Brain Syndrome Tied to Changes in the ...

Morphological differences seen in the primary somatosensory system

People With Opioid Use Disorder Have High Suicide Rate

People With Opioid Use Disorder Have High Suicide ...

Based on data from multiple sources, many opioid-overdose deaths seem to be suicides

is free, fast, and customized just for you!

Already a member?

Sign In Now »